Please remember that these discussion boards are a public forum, which means open to the public (i.e. non-CSN members) and the content can be found via internet search engines.
Members are strongly advised not to share personal identifiers such as real names, email address, telephone number, street address, etc. This information can be used to identify you and link you to the content you provide.
Other areas of CSN are restricted to members only and cannot be found by search engines.
You are now leaving Cancer Survivors Network. Click the link to continue to https://www.urotoday.com/conference-highlights/asco-2019-annual-meeting/asco-2019-prostate-cancer/112936-asco-2019-pembrolizumab-plus-docetaxel-and-prednisone-in-abiraterone-or-enzalutamide-pretreated-patients-with-mcrpc-keynote-365-study.html.